Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from National Cinemedia ( (NCMI) ).
On May 1, 2025, National CineMedia held its Annual Meeting of Stockholders, where all proposals, including the election of directors and executive compensation, were approved. The company reported a decrease in revenue for the first quarter of 2025 compared to the previous year but maintained its financial guidance. A significant development was the extension of a long-term agreement with AMC Theatres, enhancing NCM’s advertising platform and financial outlook by aligning payment structures with performance metrics. This agreement also resolved ongoing litigation, eliminating potential liabilities and streamlining operations.
Spark’s Take on NCMI Stock
According to Spark, TipRanks’ AI Analyst, NCMI is a Neutral.
National CineMedia’s overall score reflects significant financial challenges, including high debt and declining revenues. Technical indicators suggest bearish trends, and the negative P/E ratio points to overvaluation concerns. Earnings call insights and recent corporate events provide some optimism, indicating potential for recovery and future growth. However, the need for strategic improvements and addressing operational inefficiencies remains critical.
To see Spark’s full report on NCMI stock, click here.
More about National Cinemedia
National CineMedia, Inc. (NCM) is the largest cinema advertising platform in the U.S., connecting brands to young, diverse audiences through movies and pop culture. It operates over 17,500 screens in more than 1,350 theaters across 184 Designated Market Areas, including partnerships with major theater chains like AMC, Cinemark, and Regal.
Average Trading Volume: 751,452
Technical Sentiment Signal: Sell
Current Market Cap: $540.7M
See more data about NCMI stock on TipRanks’ Stock Analysis page.

